XML 36 R22.htm IDEA: XBRL DOCUMENT
v3.19.3

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 27, 2019
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | Revenues by disaggregated category were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Product revenues: |  |  |  |  |  |  |
Gross product revenues | $ | 239,916 |  |  | $ | 193,356 |  |  | $ | 704,084 |  |  | $ | 525,438 |
Discounts and allowances | (48,148 | ) |  | (30,410 | ) |  | (139,060 | ) |  | (82,384 | )
Net product revenues | 191,768 |  |  | 162,946 |  |  | 565,024 |  |  | 443,054 |
Collaboration revenues: |  |  |  |  |  |  |
License revenues (1) | 68,035 |  |  | 51,323 |  |  | 128,937 |  |  | 152,261 |
Research and development services revenues (2) | 12,988 |  |  | 10,560 |  |  | 35,814 |  |  | 27,464 |
Other collaboration revenues (3) | (1,088 | ) |  | 568 |  |  | (2,310 | ) |  | 2,445 |
Total collaboration revenues | 79,935 |  |  | 62,451 |  |  | 162,441 |  |  | 182,170 |
Total revenues | $ | 271,703 |  |  | $ | 225,397 |  |  | $ | 727,465 |  |  | $ | 625,224 |
____________________
(1) | License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo.
(2) | Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.
(3) | Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were offset by the 3% royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.
Net product revenues, License revenues and Research and development services revenues were recorded in accordance with Topic 606 for all periods presented. Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. Other collaboration revenues, which included the p rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were recorded in accordance with Topic 808 for all periods presented. Net product revenues disaggregated by product were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
CABOMETYX | $ | 187,410 |  |  | $ | 158,262 |  |  | $ | 552,315 |  |  | $ | 428,317 |
COMETRIQ | 4,358 |  |  | 4,684 |  |  | 12,709 |  |  | 14,737 |
Net product revenues | $ | 191,768 |  |  | $ | 162,946 |  |  | $ | 565,024 |  |  | $ | 443,054 |
Total revenues disaggregated by significant customer were as follows (dollars in thousands):
| Three Months Ended September 30,
| 2019 |  | 2018
| Dollars |  | Percent of Total |  | Dollars |  | Percent of Total
Ipsen | $ | 76,016 |  |  | 28 | % |  | $ | 57,186 |  |  | 25 | %
Caremark L.L.C. | 35,703 |  |  | 13 | % |  | 30,707 |  |  | 14 | %
Affiliates of McKesson Corporation | 31,901 |  |  | 12 | % |  | 26,597 |  |  | 12 | %
Affiliates of AmerisourceBergen Corporation | 25,235 |  |  | 9 | % |  | 17,232 |  |  | 8 | %
Others, individually less than 10% of Total revenues for all periods presented | 102,848 |  |  | 38 | % |  | 93,675 |  |  | 41 | %
Total revenues | $ | 271,703 |  |  | 100 | % |  | $ | 225,397 |  |  | 100 | %
| Nine Months Ended September 30,
| 2019 |  | 2018
| Dollars |  | Percent of Total |  | Dollars |  | Percent of Total
Ipsen | $ | 120,133 |  |  | 17 | % |  | $ | 145,038 |  |  | 23 | %
Caremark L.L.C. | 105,638 |  |  | 15 | % |  | 83,516 |  |  | 13 | %
Affiliates of McKesson Corporation | 88,496 |  |  | 12 | % |  | 71,249 |  |  | 11 | %
Affiliates of AmerisourceBergen Corporation | 70,503 |  |  | 10 | % |  | 49,995 |  |  | 8 | %
Others, individually less than 10% of Total revenues for all periods presented | 342,695 |  |  | 46 | % |  | 275,426 |  |  | 45 | %
Total revenues | $ | 727,465 |  |  | 100 | % |  | $ | 625,224 |  |  | 100 | %
Total revenues disaggregated by geographic region were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
U.S. | $ | 194,484 |  |  | $ | 166,270 |  |  | $ | 572,957 |  |  | $ | 453,342 |
Europe | 76,017 |  |  | 57,186 |  |  | 120,134 |  |  | 145,038 |
Japan | 1,202 |  |  | 1,941 |  |  | 34,374 |  |  | 26,844 |
Total revenues | $ | 271,703 |  |  | $ | 225,397 |  |  | $ | 727,465 |  |  | $ | 625,224 |
Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances | The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
| Chargebacks and Discounts for Prompt Payment |  | Other Customer Credits/Fees and Co-pay Assistance |  | Rebates |  | Total
Balance at December 31, 2018 | $ | 2,322 |  |  | $ | 3,038 |  |  | $ | 11,916 |  |  | $ | 17,276 |
Provision related to sales made in: |  |  |  |  |  |  |
Current period | 92,769 |  |  | 11,190 |  |  | 35,422 |  |  | 139,381 |
Prior periods | (130 | ) |  | (106 | ) |  | (85 | ) |  | (321 | )
Payments and customer credits issued | (92,317 | ) |  | (11,466 | ) |  | (33,127 | ) |  | (136,910 | )
Balance at September 30, 2019 | $ | 2,644 |  |  | $ | 2,656 |  |  | $ | 14,126 |  |  | $ | 19,426 |

X
- Definition Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] + References No definition available. + Details
Name: | exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix: | exel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration